Comparative Pharmacology
Head-to-head clinical analysis: IQUIX versus LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IQUIX versus LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
IQUIX vs LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DNA gyrase inhibitor; topoisomerase IV inhibitor; bactericidal against Gram-positive and Gram-negative bacteria by blocking DNA replication.
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
1-2 drops of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1-2 drops every 4 hours while awake for up to 5 days total.
500 mg or 750 mg intravenously once daily. Infusion over 60-90 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours. This short half-life supports twice-daily dosing in clinical practice (for ophthalmic suspension).
6-8 hours in patients with normal renal function (creatinine clearance >50 mL/min); increases to 20-48 hours in severe renal impairment (CrCl <20 mL/min); clinically relevant for dosing interval adjustment.
Primarily renal excretion of unchanged drug (approximately 70-80%). A smaller fraction is excreted as metabolites via the kidneys. Biliary/fecal elimination accounts for less than 10% of the dose.
Renal: ~87% of dose excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5% eliminated as unchanged drug and metabolites; <4% recovered in feces.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic